Aligos Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALGS research report →
Companywww.aligos.com
Aligos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.
- CEO
- Lawrence Blatt
- IPO
- 2020
- Employees
- 70
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $34.65M
- P/E
- -0.64
- P/S
- 7.37
- P/B
- 1.83
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.03%
- Op Margin
- -2033.39%
- Net Margin
- -1919.68%
- ROE
- -139.47%
- ROIC
- -212.93%
Growth & Income
- Revenue
- $2.19M · -44.59%
- Net Income
- $-24,193,000 · 81.56%
- EPS
- $-2.45 · 88.30%
- Op Income
- $-87,985,000
- FCF YoY
- -2.56%
Performance & Tape
- 52W High
- $13.69
- 52W Low
- $5.12
- 50D MA
- $6.91
- 200D MA
- $8.45
- Beta
- 2.28
- Avg Volume
- 194.52K
Get TickerSpark's AI analysis on ALGS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 9, 26 | Aneja Nikhil | other | 9,450 |
| Mar 9, 26 | Calhoun Lesley Ann | other | 37,485 |
| Mar 9, 26 | BLATT LAWRENCE | other | 105,840 |
| Jan 29, 26 | Aneja Nikhil | other | 3,800 |
| Jan 29, 26 | Aneja Nikhil | other | 2,640 |
| Jan 29, 26 | Aneja Nikhil | other | 7,155 |
| Jan 29, 26 | Aneja Nikhil | other | 3,600 |
| Jul 16, 25 | BLATT LAWRENCE | other | 179,800 |
| Jul 16, 25 | Symons Julian A. | other | 16,000 |
| Jul 16, 25 | Calhoun Lesley Ann | other | 40,185 |
Our ALGS Coverage
We haven't published any research on ALGS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALGS Report →